HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.

Abstract
To evaluate the long-term effects of entacapone on both mean daily 'on' time and health-related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing 'end-of-dose' motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12-month study was performed with an initial 3-month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries ('on' time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ-8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group (P < 0.01). The improvement in 'on' time was significantly increased since the 3-month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ-8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing 'on' time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment.
AuthorsF Grandas, B Hernández, PRACTICOMT Study Group
JournalEuropean journal of neurology (Eur J Neurol) Vol. 14 Issue 3 Pg. 282-9 (Mar 2007) ISSN: 1468-1331 [Electronic] England
PMID17355548 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Catechols
  • Nitriles
  • Levodopa
  • entacapone
Topics
  • Aged
  • Antiparkinson Agents (administration & dosage, adverse effects)
  • Catechols (administration & dosage, adverse effects)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced (drug therapy, physiopathology, prevention & control)
  • Early Diagnosis
  • Female
  • Humans
  • Interviews as Topic
  • Levodopa (administration & dosage, adverse effects)
  • Male
  • Middle Aged
  • Nitriles (administration & dosage, adverse effects)
  • Parkinson Disease (drug therapy, physiopathology, psychology)
  • Patient Compliance
  • Patient Satisfaction
  • Prospective Studies
  • Quality of Life
  • Time
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: